Table 1 Immunohistochemical results of EZHIP in our series
Tumor types | EZHIP [n (%)] |
|---|---|
Diffuse astrocytic and oligodendroglial tumors | |
Astrocytoma, IDH-mutant, grade 2 | 0/2 (0) |
Oligodendroglioma, IDH-mutant and 1p19q codeleted, grade 2 | 0/3 (0) |
Epithelioid glioblastoma | 0/1 (0) |
Astrocytoma, IDH-mutant, grade 4 | 0/3 (0) |
DMG, H3K27-mutant | 0/24 (0) |
DMG, H3K27-WT with EZHIP overexpression | 13/13 (100) |
HGG with MSI | |
CMMRD | 0/6 (0) |
Lynch syndrome | 0/4 (0) |
Diffuse glioma, H3.3 G34-mutant | 0/10 (0) |
HGG, MYCN-amplified | 0/9 (0) |
Glioblastoma, IDH-WT | 0/10 (0) |
Other astrocytic tumors | |
Pilocytic astrocytoma | 0/10 (0) |
High-grade astrocytoma with piloid features | 0/1 (0) |
Pleomorphic xanthoastrocytoma with anaplastic features | 0/9 (0) |
Ependymal tumors | |
Myxopapillary ependymoma | 0/6 (0) |
Posterior fossa ependymoma | |
Group PFA | 47/47 (100) |
Group PFA, H3K27-mutant | 0/2 (0) |
Group PFB | 0/19 (0) |
Supratentorial EPN | |
YAP1-fusion-positive | 0/5 (0) |
C11orf95 fusion-positive | 0/17 (0) |
Subependymoma | 0/2 (0) |
Neuronal and mixed neuronal-glial tumors | |
Diffuse leptomeningeal glioneuronal tumor | 0/1 (0) |
Tumors of the pineal region | |
Pineoblastoma | 0/10 (0) |
Embryonal tumors | |
Medulloblastoma, group 3 | 0/5 (0) |
Medulloblastoma, group 4 | 0/5 (0) |
Medulloblastoma, SHH-activated | 0/10 (0) |
Medulloblastoma, WNT-activated | 1/10 (10)a |
Embryonal tumors with multilayered rosettes, C19MC-amplified | 0/10 (0) |
AT/RT | |
AT/RT MYC | 1/3 (33)a |
AT/RT SHH | 0/4 (0) |
AT/RT TYR | 0/3 (0) |
CNS tumor with BCOR internal tandem duplication | 0/8 (0) |
CNS high-grade neuroepithelial tumor with MN1 alteration | 0/8 (0) |
Germ cell tumors | |
Germinoma | 29/31 (94) |